Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for pyridostigmine

  1. Efgartigimod for treating generalised myasthenia gravis [ID4003]

    In development [GID-TA10986] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Orthostatic hypotension treatment:- For people with Parkinson's disease, what is the most effective pharmacological treatment for orthostatic hypotension?Particular interventions and comparisons of interest are:- midodrine compared with fludrocortisone (primary comparison)- pyridostigmine- ephedrine - pseudoephedrine.

    are:- midodrine compared with fludrocortisone (primary comparison)- pyridostigmine- ephedrine - pseudoephedrine. Any explanatory...

    Research recommendation
    Published
    15 October 2018

  3. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

    NICE guideline
    Published
    19 July 2017
    View recommendations

    Sections for NG71

  4. Research recommendations

    are:- midodrine compared with fludrocortisone (primary comparison)- pyridostigmine- ephedrine - pseudoephedrine. NG71/2